Longevity InTime: Autonomous AI Institute. Anti-Aging Digital Health Immortality Transhumanist AI Channel

ICON Partners with Anthropic ICON, a contract research organization, announced a multi-year partnership with Anthropic on July 28. The company plans to utilize Claude in its Orbis platform for tasks such as clinic selection, risk assessment of enrollment disruption, protocol modeling, and client access to ICON's data and expertise. The clinical trial process often loses time before the first patient receives treatment. Sponsors select hospitals and clinics with patients who have the desired diagnosis and characteristics, then the team agrees on a protocol, including participant inclusion criteria, laboratory tests, and observation frequency. Each protocol amendment sends the document back for approval, delaying the start. The announcement described four tasks for Claude: OneSearch and OnePlan will aid in center selection and evaluation, a predictive analytics system will identify risk signals in ongoing trials, such as enrollment deviations from the plan, and another tool will model protocol variants before document submission to identify potential future amendments. According to Pip White, Anthropic's leader in Ireland, the UK, and Northern Europe, delays are primarily due to participant enrollment: "participant enrollment is one of the biggest bottlenecks in clinical development, causing up to 80% of trials to be delayed". The medication reaches the first patient after a series of organizational decisions, including finding a suitable center, agreeing on a protocol, and recruiting participants who meet the protocol's conditions. ICON conducts trials for pharmaceutical and biotechnology companies and plans to integrate AI into these repetitive decisions, using Claude to aid teams in making decisions before clinical data appears, specifically in center selection, enrollment planning, and protocol preparation, as reported in undisclosed clinical development publications. 🔗 Read original →